EuroClonality二代测序区分蕈样肉芽肿与炎症并检测循环肿瘤细胞
该研究对33例蕈样肉芽肿(MF)和10例炎症性皮肤病患者行皮肤与血液TRB/TRG二代测序。采用基于丰度与分布的克隆判定法可高敏(88%)高特(90%)区分MF与炎症,并在46%早期和60%晚期MF患者血中检出循环肿瘤细胞。
要点
- 基于丰度与分布的克隆判定可提高MF与炎症性皮肤病鉴别特异性。
- 标准丰度阈值下MF与炎症性皮肤病均可检出克隆性重排,特异性不足。
- NGS可在近半数早期MF患者血中检出循环肿瘤细胞。
核心结论
- 基于二代测序的T细胞受体库分析是区分早期MF与炎症性皮肤病的高敏高特方法,并可灵敏检测循环肿瘤细胞。
研究设计与样本
- 研究纳入33例MF患者和10例炎症性皮肤病患者,分析皮肤活检与血液样本的TRB和TRG二代测序。
主要发现
- 应用标准丰度阈值时,97%(32/33)MF患者皮肤DNA检出至少一个克隆性重排,炎症性皮肤病患者为90%(9/10)。
- 采用基于丰度与分布的方法仅将显著偏离生理背景的重排判为克隆性,MF为29/33,炎症性皮肤病为1/10。
- 该方法的鉴别敏感度为88%、特异度为90%。
- 早期MF患者循环肿瘤细胞检出率为46%(11/24),晚期MF为60%(3/5)。
临床怎么用
- 对早期MF与炎症性皮肤病鉴别困难时,可考虑采用基于丰度与分布的NGS T细胞受体库分析辅助诊断。
- NGS可用于MF患者循环肿瘤细胞的分子检测。
局限性
- 研究样本量较小(MF 33例、炎症性皮肤病10例),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycosis fungoides (MF) is a rare malignancy that is characterized by the presence of circulating tumour cells (CTCs) in a subgroup of patients. Reliably distinguishing MF from inflammatory skin conditions is challenging. OBJECTIVES: To evaluate the potential benefits of next-generation sequencing (NGS)-based T-cell receptor rearrangement repertoire analysis in detecting clonal rearrangements in MF and inflammatory skin conditions. METHODS: Skin biopsies and blood samples from 33 patients with MF and 10 patients with inflammatory skin conditions were analysed using TRB and TRG NGS. Twenty-seven patients had early-stage IA (n = 19) and IB (n = 8) MF, and six had advanced-stage disease (IIB, n = 5; IIIA, n = 1). RESULTS: Analysis applying standard abundance thresholds identified at least one clonal rearrangement in the skin DNA of 97% (n = 32/33) of patients with MF and in 90% (n = 9/10) of those with inflammatory skin conditions. To enhance specificity, an abundance and distribution-based approach was applied, which considered only rearrangements that significantly stood out from the physiological background as clonal (MF, n = 29/33; inflammatory skin conditions, n = 1/10), allowing for highly sensitive (88%) and specific (90%) discrimination between MF and other inflammatory skin conditions. CTCs were detected in 46% (n = 11/24) of patients with early-stage MF and in 60% (n = 3/5) of those with late-stage MF. CONCLUSIONS: NGS-based T-cell receptor repertoire analysis is a highly sensitive and specific method for the differential diagnosis of early-stage MF vs. inflammatory skin conditions, and for the sensitive molecular detection of CTCs. Mycosis fungoides (or ‘MF’ for short) is a rare cancer. In some people, cancer cells can be found in their blood. Conditions like eczema can look very similar to MF. It can be hard to distinguish MF from such inflammatory skin conditions. We looked at whether it is possible to distinguish inflammation from cancer with a genetic technique called ‘next-generation sequencing’. Using this technique, we can detect whether completely identical cells are present (called ‘clonal rearrangements’), which can indicate MF. Skin and blood samples from 33 people with MF and from 10 people with other inflammatory skin conditions were analysed with NGS. Most people with MF were in early disease stages. Those in the early stages of the disease are the most likely to be incorrectly diagnosed. There is a standard approach to performing NGS analysis. When using this approach, most people with MF had clonal rearrangements, but so did people with other inflammatory skin conditions. Therefore, we checked how these rearrangements were distributed in each person. By doing this, we were able to tell MF apart from other inflammatory skin conditions in almost all cases. We also looked at the blood samples and found tumour cells in almost half of people with MF. In conclusion, our approach is a highly sensitive and specific method to identify people with early-stage MF.
引用
- Wehkamp U, Pietzka S, Kotrová M, et al. Mycosis fungoides: differentiation from inflammation and detection of circulating tumour cells with the EuroClonality next-generation sequencing assay. Br J Dermatol. 2025. PMID: 39475451. doi:10.1093/bjd/ljae425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。